



ASX Announcement

27 August 2026

Resignation/Appointment of Company Secretary and Communication Person

Sydney, Australia; 27 August 2026: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), advises, in accordance with ASX Listing Rule 3.16.1, that Mr Mark Licciardo has resigned as Company Secretary, effective 27 August 2026.

The Board thanks Mr Licciardo for his service as Company Secretary.

The Company is pleased to announce the appointment of Ms Olga Smejkalova from Acclime Australia as Company Secretary, effective 27 August 2026. Ms Smejkalova is an experienced governance professional with extensive expertise in corporate governance, regulatory compliance and company secretarial practice. The Board looks forward to her contribution in this role.

In accordance with ASX Listing Rule 12.6, the Company also advises that Olga Smejkalova, Company Secretary, and Mr Karolis Rosickas, Chief Executive Officer, have been appointed as the persons responsible for communication with ASX in relation to Listing Rule matters.

- ENDS -

This announcement has been authorised for release by the Board of Directors.

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio